Physician profile
John M Miller
NPI 1972698009
$29,739.54
in general payments reported to CMS, 2019-2025
12 companies · $1,161 in 2025
The $1,161 reported for 2025 was more than what a typical Foot & Ankle Surgery provider received nationally (typical 2025 total: $424).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $9,200 · 2020: $5,889 · 2021: $4,390 · 2022: $739 · 2023: $876 · 2024: $7,484 · 2025: $1,161.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $7,150 · Travel and Lodging: $1,881 · Food and Beverage: $491.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $7,150.00 |
| Travel and Lodging | $1,881.29 |
| Food and Beverage | $490.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Flower Orthopedics Coporation | $16,622.55 | 2019-2022 | |
| Fusion Orthopedics USA, LLC | $8,265.22 | 2024-2025 | |
| Stryker Corporation | $3,528.04 | 2019-2024 | Inbone, Salvation |
| Fusion Orthopedics, LLC. | $859.94 | 2023 | |
| Paragon 28, INC. | $196.29 | 2020-2025 | Portfolio |
| Horizon Therapeutics Plc | $68.45 | 2019-2020 | |
| Novo Nordisk INC | $62.23 | 2019-2025 | Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $49.12 | 2019-2020 | |
| Triad Life Sciences INC. | $40.91 | 2022 | |
| Janssen Pharmaceuticals, INC | $29.94 | 2019-2020 | |
| Exact Sciences Corporation | $16.85 | 2024 | Cologuard Collection Kit |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$1,447,108.22 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Miller listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.